Bloom Science announced the launch of PH1, its proprietary platform designed to develop microbiome-based therapeutics for rare and severe forms of epilepsy. According to the company, PH1 integrates microbial genomics, neuroscience and bioinformatics to identify bacterial strains that produce neuromodulatory metabolites.
The company said the platform’s initial focus is on genetic epilepsies that lack effective treatment options. Bloom Science claims PH1 aims to harness microbiome-derived compounds to influence neural circuits involved in seizure activity.
According to the company, PH1 builds on evidence linking gut microbiota to brain function and leverages targeted bacterial engineering to optimize therapeutic effects. Bloom Science said the platform supports the discovery and development of live biotherapeutic products designed to deliver precise metabolic interventions.
Bloom Science claims its approach could expand beyond epilepsy to address other neurological and neurodevelopmental disorders by targeting shared pathways in the gut-brain axis. The company said it plans to advance candidate therapies identified through PH1 into preclinical and clinical testing.
The company also noted its team combines expertise in microbiology, neuroscience and computational biology to guide program development. Bloom Science claims PH1 represents a new frontier in using microbiome science to treat central nervous system disorders that remain underserved by current therapies.
